A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 900 participants.

Also called NCT07230730

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 900 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07230730
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07230730. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-13 (actual); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Drug)
SHR-1918
Intervention (Drug)
SHR-1918 placebo
Lead sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07230730
Content hash
94a5c055bef680d4ac6b4061ee8b236cf9146b8a3565d6f8b662e9229868436e